ArticleCureus2026
Multiple Evanescent White Dot Syndrome After mRNA COVID-19 Vaccination.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A 46-year-old woman noticed blurred vision in her right eye two weeks after receiving the fourth dose of a COVID-19 vaccine and visited a local eye clinic. Then, the patient was referred to our hospital to investigate the cause of decreased vision in the right eye. At the initial visit to our hospital, the best-corrected visual acuity (BCVA) in the right eye was 0.7 in decimal units and 1.5 in the left eye, respectively. Intraocular pressure was 17 mmHg in both eyes. Abnormal findings were observed only in the right eye; the left eye was completely normal. Therefore, all abnormal findings described below are related to the right eye. Anterior segment examination revealed inflammatory cells in the anterior chamber. The lenses in both eyes were almost clear, and the right eye showed vitreous cells and vitreous opacity. Fundus examination revealed multiple small white exudative spots. Optical coherence tomography (OCT) demonstrated disruption of the ellipsoid zone (EZ) and hyper-reflective lesions beneath the retina. Fluorescein angiography (FA) showed hyperfluorescence consistent with staining at the sites of exudative lesions, while indocyanine green angiography (ICGA) revealed corresponding hypofluorescent spots due to blocked fluorescence. Full-field electroretinography (ERG) showed reduced amplitudes of both a- and b-waves. Goldman perimetry identified a central scotoma in the right eye. Based on these findings, the patient was diagnosed with multiple evanescent white dot syndrome (MEWDS) in the right eye. Topical betamethasone sodium phosphate and fradiomycin sulfate were initiated six times a day for the right eye at the first visit. The day after the initial visit, the BCVA in the right eye rapidly declined to 0.01 in decimal units, prompting the initiation of oral prednisolone at 30 mg/day. Eight days later, a sub-Tenon's capsule injection of triamcinolone acetonide (20 mg/0.5 ml) was administered. The symptoms gradually improved thereafter, and the hyper-reflective subretinal lesions observed on OCT disappeared. Oral steroid therapy was tapered, and the visual acuity (VA) improved to 1.0 in decimal units four months later. A case of MEWDS occurring after COVID-19 vaccination showed favorable recovery with oral steroid therapy and sub-Tenon's injection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.